undamentalytics Newsletter
Sign in

Neuphoria Therapeutics Inc. balance sheet

At the end of fiscal 2026, Neuphoria Therapeutics Inc. had total assets of $28.7m, total liabilities of $4.1m and shareholders' equity of $24.6m. It held $19.9m in cash against $0 of debt: net cash of $19.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2025Jun 20252026Jun 2026
Cash and equivalents1420
Receivables01
Total current assets1521
Goodwill93
Total assets2929
Accounts payable10
Total current liabilities41
Total debt00
Total liabilities104
Shareholders' equity1925
Net debt (negative = net cash)−14−20
Shares outstanding2m5m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neuphoria Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuphoria Therapeutics Inc.